Syndax Pharmaceuticals (SNDX) Change in Account Payables (2015 - 2026)

Syndax Pharmaceuticals' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$5.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 263.33% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at $796000.0 (down 35.7% YoY), while the FY2025 annual figure was $5.0 million, up 197.54% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$5.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Change in Account Payables was $7.3 million in Q2 2025, with the low at -$6.7 million in Q3 2024.
• The 5-year median for Change in Account Payables is $676000.0 (2022), against an average of $304352.9.
• Peak annual rise in Change in Account Payables reached 262.97% in 2023, while the deepest fall reached 829.29% in 2023.
• Syndax Pharmaceuticals' Change in Account Payables stood at -$2.8 million in 2022, then jumped by 241.53% to $3.9 million in 2023, then surged by 71.98% to $6.7 million in 2024, then sank by 59.07% to $2.8 million in 2025, then plunged by 308.32% to -$5.7 million in 2026.
• Business Quant data shows SNDX's Change in Account Payables at -$5.7 million in Q1 2026, $2.8 million in Q4 2025, and -$3.5 million in Q3 2025.